Recomienda este artículo a tus amigos:
Benefit-Risk Assessment in Pharmaceutical Research and Development - Chapman & Hall / CRC Biostatistics Series 1.º edición
Precio
$ 79,49
sin IVA
Pedido desde almacén remoto
Entrega prevista 23 de jun. - 10 de jul.
Nuestros clientes opinan:
Añadir a tu lista de deseos de iMusic
Benefit-Risk Assessment in Pharmaceutical Research and Development - Chapman & Hall / CRC Biostatistics Series
Bringing together the expertise of 15 contributors from academia and the industry, this book offers an easy-to-read guide to the various facets of benefit-risk assessment in the major stages of pharmaceutical R&D, from early clinical development to late-stage development to regulatory review to post-launch assessment. Suitable for those in b
220 pages
| Medios de comunicación | Libros Paperback Book (Libro con tapa blanda y lomo encolado) |
| Publicado | 30 de junio de 2020 |
| ISBN13 | 9780367576240 |
| Editores | Taylor & Francis Ltd |
| Páginas | 220 |
| Dimensiones | 150 × 220 × 10 mm · 410 g |
| Lengua | Inglés |
| Editor | Felli, James (Eli Lilly and Company, Indianapolis, Indiana, USA) |
| Editor | Noel, Rebecca (Eli Lilly and Company, Indianapolis, Indiana, USA) |
| Editor | Sashegyi, Andreas (Eli Lilly and Company, Indianapolis, Indiana, USA) |
